MALT Lymphoma Prognostic Index (MALT-IPI)
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–0
- Intermediate Risk1–1
- High Risk2–3
The MALT Lymphoma Prognostic Index (MALT-IPI) calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include age. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.
Clinical Indication
The MALT Lymphoma Prognostic Index (MALT-IPI) is indicated for bedside clinical practice to support Identifies MALT lymphoma patients at risk for poor outcomes using three clinical parameters: age ≥70 years, Ann Arbor stage III/IV, and elevated lactate dehydrogenase (LDH). Stratifies patients into low, intermediate, and high risk groups predictive for event-free survival and overall survival.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Prognostic utility retained across different treatment arms (chlorambucil, rituximab, rituximab plus chlorambucil).
MALT-IPI Score = Age points + LDH points + Ann Arbor Stage points. Age ≥70 years (1 point), elevated LDH (1 point), Ann Arbor stage III/IV (1 point). Total score 0 = Low risk, 1 = Intermediate risk, ≥2 = High risk.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient age in years. Age ≥70 years is associated with worse prognosis (HR 1.72, 95% CI 1.26-2.33)(years) |
| ldh_level | string | Yes | Serum lactate dehydrogenase (LDH) level relative to upper limit of normal. Elevated LDH is associated with worse prognosis (HR 1.87, 95% CI 1.27-2.77) |
| ann_arbor_stage | string | Yes | Ann Arbor staging system for lymphomas. Stage III/IV disease is associated with worse prognosis (HR 1.79, 95% CI 1.35-2.38) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Low Risk | Low risk of poor outcomes |
| 1–1 | Intermediate Risk | Intermediate risk of poor outcomes |
| 2–3 | High Risk | High risk of poor outcomes |
Evidence-Based References (EBM)
- Thieblemont C, Cascione L, Conconi A, Kiesewetter B, Raderer M, Gaidano G, et al. A MALT lymphoma prognostic index. Blood. 2017 Sep 21;130(12):1409-1417. doi: 10.1182/blood-2017-03-771915.DOI: 10.1182/blood-2017-03-771915
- Hong J, Lee Y, Park J, Kim SJ, Lim ST, Kim JS, et al. Validation of the MALT-lymphoma international prognostic index (MALT-IPI) and extension of the prognostic model with the addition of β2-microglobulin. Ann Hematol. 2019 Nov;98(11):2499-2507. doi: 10.1007/s00277-019-03808-x.DOI: 10.1007/s00277-019-03808-x
- Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Agent Alone. J Clin Oncol. 2017 Jun 10;35(17):1905-1912. doi: 10.1200/JCO.2016.70.6994.DOI: 10.1200/JCO.2016.70.6994
Related calculators
- Mantle Cell Lymphoma International Prognostic Index (MIPI)
- International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)
- Follicular Lymphoma International Prognostic Index (FLIPI)
- International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)
- National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI)